FDA
15th December 2015

Currently Approved Ezetimibe is Denied Additional Claim by FDA

Yesterday, the Endocrinologic and Metabolic Drug Advisory Committee (EMDAC) convened to discuss ezetimibe (Zetia), which is currently approved for lowering LDL cholesterol levels.

Currently Approved Ezetimibe is Denied Additional Claim by FDA

Yesterday, the Endocrinologic and Metabolic Drug Advisory Committee (EMDAC) convened to discuss ezetimibe (Zetia), which is currently approved for lowering LDL cholesterol levels. Merck/Schering-Plough sought to expand the use of ezetimibe with the additional claim that by adding ezetimibe to statin therapy, acute coronary syndrome (ACS) patients could reduce their risk of cardiovascular events. However, the Agency ruled that new data was not sufficient to expand the drug’s indication.

During the Advisory Committee meeting, the panel voted that the safety and efficacy data from a large morbidity and mortality trial, IMPROVE-IT, did not support the expanded indication for cardiovascular event reduction (5 yes, 10 no, 0 abstentions).

The vote relied primarily on the results from the IMPROVE- IT trail, which was an 18,000- patient study. IMPROVE-IT showed that over the course of a 7 year follow-up, adding ezetimibe to simvastatin significantly reduced cardiovascular death, MI, unstable angina requiring rehospitalization, coronary revascularization and stroke by 6.4% when compared to patients who received simvastatin alone.

The Agency expressed their doubt in justifying the expanded indication. “There was a weak and not particularly robust effect,” stated Dr. Susan R Heckbert (University of Washington, Seattle). Nevertheless, Panel chair Dr. Robert J Smith (Brown University, Providence, RI) noted that this vote was particularly difficult. “I do think this is a positive, albeit modest, trial. I don’t think it communicates that this drug is not effective in lowering risk; I suspect that it is effective. However, we just don’t know that yet,” said Dr. Smith.

The agency is not obligated to follow its panel’s recommendation, but normally does so. 

White Oak Gude

 

Recent Related Articles

Best Tips for Medical Device Manufacturers to Write a Compelling Substantial Equivalence Section for their FDA 510k Submission
01 July 2020
Best Tips for Medical Device Manufacturers to Write a Compelling Substantial Equivalence Section for their FDA 510k Submission

Over the past few years, the number of ex-US manufacturers submitting a Class II exempt 510k device registration has increased substantially. For companies with medical devices that are approved and successful in a foreign market, the logical next step is to introduce their product into the US, which has one of the most lucrative healthcare markets in the world. Read more

Evolving FDA Thinking on Advisory Committee Meetings Related to Foods, Drugs, and Devices
25 June 2020
Evolving FDA Thinking on Advisory Committee Meetings Related to Foods, Drugs, and Devices

FDA advisory committee meetings are important regulatory events for many manufacturers on the path to marketing approval. These meetings can quite literally result in the approval or rejection of a product based on the panel’s vote. Read more

NDA vs. OTC Monograph: Which Pathway is Right for You?
22 June 2020
NDA vs. OTC Monograph: Which Pathway is Right for You?

One of the main challenges our clients face is determining which regulatory pathway is best for their products. For example, what if an OTC product has a Monograph active ingredient but that ingredient is present at a different amount than the permitted amount? Or what if the label claims a novel indication not specified in a Monograph? If you are debating pursuit of either regulatory pathway for your OTC drug, it is critical to consider cost, timeline, and label claims to ensure your products has a unique stance in today’s market. Read more

4 Problems Importing Rapid Antibody Tests for Coronavirus
19 June 2020
4 Problems Importing Rapid Antibody Tests for Coronavirus

US distributors and agents trying to import rapid antibody tests for coronavirus face a number of obstacles. The good news is that FDA has opened up the Emergency Use Authorization (EUA) program to include SARS-CoV-2 (the virus) and COVID-19 (the disease), expediting time to market. Read more

Let’s work together

The journey to scientific and commercial success is often complex and always critical, if you are looking for an expert partner to help steer you to confident solutions, contact us today

Contact us